Cancer Discov. 2014 Jan;4(1):OF8. doi: 10.1158/2159-8290.CD-NB2013-131. Epub 2013 Sep 19.
In a phase III trial for patients with metastatic renal cell carcinoma, pazopanib and sunitinib offered comparable progression-free survival, but pazopanib scored higher on quality-of-life indices.
在一项转移性肾细胞癌患者的 III 期临床试验中，帕唑帕尼和舒尼替尼提供了相当的无进展生存期，但帕唑帕尼在生活质量指数上得分更高。
Zotero 插件